Hemangioendothelioma clinical trials
The registry lists 7 studies for Hemangioendothelioma across 7 countries. 3 are recruiting or about to start. 3 of them are mainly about Hemangioendothelioma (how this is decided). Per ClinicalTrials.gov, last updated 2026-03-17.
Get an email when these change. Save the Hemangioendothelioma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Shanghai Children's Medical Center (1) · Guerbet (1) · Institut Bergonié (1) · Grupo Espanol de Investigacion en Sarcomas (1) · West China Hospital (1) · Boston Children's Hospital (1) · Yonsei University (1)
What is being tested here
Drugs under test in Hemangioendothelioma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Sirolimus | 1 | 0 | 2 |
| Everolimus | 1 | 0 | 1 |
| Trabectedin | 0 | 0 | 1 |
| Nivolumab | 0 | 0 | 1 |
Drug classes tested here mTOR inhibitors 2 open
Who these studies take
Of the 1 Hemangioendothelioma studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 1 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (100%) | 1 (100%) |
| 18 | 0 (0%) | 0 (0%) |
| 30 | 0 (0%) | 0 (0%) |
| 40 | 0 (0%) | 0 (0%) |
| 50 | 0 (0%) | 0 (0%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 7 studies, recruiting or not: 43% stop at 75 or younger and 43% at 65; 71% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. search them.
- A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular AnomaliesNot yet recruitingNCT07477548Phase 2
- Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform HemangioendotheliomaRecruitingNCT05324384Phase 21 country
- Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)Not yet recruitingNCT04406870Phase 41 country
- Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma PatientsCompletedNCT04008238Not applicable1 country
- A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization ProceduresCompletedNCT02625389Phase 41 country
- Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasCompletedNCT03277924Phase 1/23 countries
- A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular TumorsTerminatedNCT02110069Phase 21 country